Mark Wilterding insider trades: RxSight (RXST) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | RXST | ↓ Sell | 7,765 | $6.96 | $54K | Direct | Sep 2, 2026 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RXST insiders
Open-market trades in the last 12 months
About Mark Wilterding's insider trades
Mark Wilterding is Chief Financial Officer at RxSight (RXST). Since Sep 2, 2026, Mark has reported no open-market purchases and 1 sale worth $54K on SEC Form 4. In the last 12 months: 1 sale ($54K).
Their filings also include option exercises (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RXST insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.